Penthrane
(Methoxyflurane)Phase 3Small molecule
Methoxyflurane is an inhaled anesthetic gas used to put patients to sleep during surgery and other medical procedures. It can also be used in low doses for pain relief in emergency situations.[1] Penthrane is currently being investigated across 4 indications[3], with its most advanced program in Phase 3.[1]
Penthrane is one of 37 small molecule programs targeting Pain. It is currently in Phase 3.
4
Indications
20
Total Trials
4
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
216 competitors in Acute Myocardial Infarction
#DrugCompanyPhaseTrials
1Lovenox
SanofiPhase 3
Byetta
AstraZenecaPhase 3
Kineret
SSwedish Orphan Biovitrum
Phase 3
Jardiance
Boehringer IngelheimPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Reopro
Boehringer IngelheimPhase 3
Glucophage
EMD SeronoPhase 3
Xarelto
WWim Janssens
Phase 3
Allegra
CChattem
Phase 3
Penthrane
PPurdue Pharma, Canada
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Analgesia3 trials
Efficacy and Safety2 trials
Pain Management2 trials
Acute Myocardial Infarction1 trial
BPH1 trial
11 more indications
Treatment1 trial
Pain Control1 trial
Local Anesthetic1 trial
Occupational Exposure1 trial
Local1 trial
Intravenous1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Methoxyflurane. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- GABA-a Receptor; Anion Channel Positive Modulator; Glycine Receptor (alpha-1/beta) Agonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPurdue Pharma, Canada